Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

被引：4
|
作者：
Paz-Ares, L. [1 ,2 ]
Tan, E. H. [3 ]
Zhang, L. [4 ]
Hirsh, V. [5 ]
O'Byrne, K. [6 ,7 ]
Boyer, M. [8 ]
Yang, J. C-H. [9 ,10 ]
Mok, T. S. K. [11 ]
Lee, K. H. [12 ]
Lu, S. [13 ]
Shi, Y. [14 ,15 ]
Kim, S-W. [16 ]
Laskin, J. [17 ]
Kim, D-W. [18 ]
Laurie, S. [19 ]
Kolbeck, K. [20 ]
Fan, J. [21 ]
Dodd, N. [22 ]
Maerten, A. [23 ]
Park, K. [24 ]
机构：
[1] Hosp Univ Doce Octubre, Med Oncol, Madrid, Spain
[2] CNIO, Madrid, Spain
[3] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[4] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[5] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[6] Princess Alexandra Hosp, Med Oncol, Brisbane, Qld, Australia
[7] Queensland Univ Technol, Brisbane, Qld, Australia
[8] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia
[9] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[10] Natl Taiwan Univ, Taipei, Taiwan
[11] Chinese Univ Hong Kong, Dept Clin Oncol, Key Lab South China, Hong Kong, Hong Kong, Peoples R China
[12] Yeungnam Univ, Med Ctr, Chungbuk Natl Univ Hosp, Cheongju, Chungbuk, South Korea
[13] Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[14] Chinese Acad Med Sci, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[15] Peking Union Med Coll, Beijing, Peoples R China
[16] Asan Med Ctr, Oncol, Seoul, South Korea
[17] Univ British Columbia, Med Oncol, Vancouver Gen Hosp, BC Canc Agcy, Vancouver, BC, Canada
[18] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam Si, South Korea
[19] Ottawa Hosp, Med Oncol, Reg Canc Ctr, Ottawa, ON, Canada
[20] Karolinska Univ Hosp Solna, Pulm Dis, Stockholm, Sweden
[21] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[22] Boehringer Ingelheim Ltd UK, BDS, Bracknell, Berks, England
[23] Boehringer Ingelheim GmbH & Co KG, TA Oncol, Ingelheim, Germany
[24] Sungkyunkwan Univ, Div Hematol Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw435.42
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA43
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
    Park, K.
    Tan, E. H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
    Hirsh, V.
    Park, K.
    Tan, E. H.
    Zhang, L.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C. H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S. W.
    Laskin, J.
    Kim, D. W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Paz-Ares, L.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S184 - S184
  • [3] Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)
    Corral, J.
    Park, K.
    Yang, J. C-H.
    Mok, T.
    Tan, E-H.
    O'Byrne, K.
    Hirsh, V.
    Boyer, M.
    Fan, J.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
    Schuler, M.
    Tan, E-H.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T. S. K.
    Hirsh, V.
    Yang, J. C-H.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Arvis, C. Dubos
    Kolbeck, K.
    Massey, D.
    Fan, J.
    Paz-Ares, L.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    Paz-Ares, L.
    Tan, E. -H.
    O'Byrne, K.
    Zhang, L.
    Hirsh, V.
    Boyer, M.
    Yang, J. C. -H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Lee, D. H.
    Laskin, J.
    Kim, D. -W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Marten, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 270 - 277
  • [6] Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: LUX-Lung 7
    Hirsh, Vera
    Park, Keunchil
    Tan, Eng-Huat
    Zhang, Li
    O'Byrne, Kenneth
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Fan, Jean
    Massey, Dan
    Paz-Ares, Luis
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [7] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [8] Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7
    Sequist, L.
    Wu, Y-L.
    Schuler, M.
    Kato, T.
    Yang, J. C-H.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Peil, B.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
    Park, K.
    Tan, E-H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T.
    Kim, M.
    Massey, D.
    Zazulina, V.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 161 - 162
  • [10] Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC in LUX-Lung 3, 6 and 7
    Sequist, L. V.
    Wu, Y.
    Schuler, M.
    Kato, T.
    Yang, J. C.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Paz-Ares, L.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Tang, W.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1572 - S1572
12345